Global Next Generation Cancer Diagnostics Market Size, Status and Forecast 2020-2026

1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Next Generation Cancer Diagnostics Revenue
• 1.4 Market by Type
  • 1.4.1 Global Next Generation Cancer Diagnostics Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Next Generation Sequencing
  • 1.4.3 qPCR & Multiplexing
  • 1.4.4 DNA Microarrays
  • 1.4.5 Other
• 1.5 Market by Application
  • 1.5.1 Global Next Generation Cancer Diagnostics Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Global Growth Trends

• 2.1 Global Next Generation Cancer Diagnostics Market Perspective (2015-2026)
• 2.2 Global Next Generation Cancer Diagnostics Growth Trends by Regions
  • 2.2.1 Next Generation Cancer Diagnostics Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Next Generation Cancer Diagnostics Historic Market Share by Regions (2015-2020)
  • 2.2.3 Next Generation Cancer Diagnostics Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Next Generation Cancer Diagnostics Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Next Generation Cancer Diagnostics Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Next Generation Cancer Diagnostics Players by Market Size
  • 3.1.1 Global Top Next Generation Cancer Diagnostics Players by Revenue (2015-2020)
  • 3.1.2 Global Next Generation Cancer Diagnostics Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Next Generation Cancer Diagnostics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Next Generation Cancer Diagnostics Market Concentration Ratio
  • 3.2.1 Global Next Generation Cancer Diagnostics Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Next Generation Cancer Diagnostics Revenue in 2019
• 3.3 Next Generation Cancer Diagnostics Key Players Head office and Area Served
• 3.4 Key Players Next Generation Cancer Diagnostics Product Solution and Service
• 3.5 Date of Enter into Next Generation Cancer Diagnostics Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

• 4.1 Global Next Generation Cancer Diagnostics Historic Market Size by Type (2015-2020)
• 4.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

• 5.1 Global Next Generation Cancer Diagnostics Market Size by Application (2015-2020)
• 5.2 Global Next Generation Cancer Diagnostics Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Next Generation Cancer Diagnostics Market Size (2015-2020)
• 6.2 Next Generation Cancer Diagnostics Key Players in North America (2019-2020)
• 6.3 North America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 6.4 North America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Next Generation Cancer Diagnostics Market Size (2015-2020)
• 7.2 Next Generation Cancer Diagnostics Key Players in Europe (2019-2020)
• 7.3 Europe Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 7.4 Europe Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

8 China

• 8.1 China Next Generation Cancer Diagnostics Market Size (2015-2020)
• 8.2 Next Generation Cancer Diagnostics Key Players in China (2019-2020)
• 8.3 China Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 8.4 China Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Next Generation Cancer Diagnostics Market Size (2015-2020)
• 9.2 Next Generation Cancer Diagnostics Key Players in Japan (2019-2020)
• 9.3 Japan Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 9.4 Japan Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Next Generation Cancer Diagnostics Market Size (2015-2020)
• 10.2 Next Generation Cancer Diagnostics Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 10.4 Southeast Asia Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

11 India

• 11.1 India Next Generation Cancer Diagnostics Market Size (2015-2020)
• 11.2 Next Generation Cancer Diagnostics Key Players in India (2019-2020)
• 11.3 India Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 11.4 India Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Next Generation Cancer Diagnostics Market Size (2015-2020)
• 12.2 Next Generation Cancer Diagnostics Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Next Generation Cancer Diagnostics Market Size by Type (2015-2020)
• 12.4 Central & South America Next Generation Cancer Diagnostics Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Cepheid
  • 13.1.1 Cepheid Company Details
  • 13.1.2 Cepheid Business Overview
  • 13.1.3 Cepheid Next Generation Cancer Diagnostics Introduction
  • 13.1.4 Cepheid Revenue in Next Generation Cancer Diagnostics Business (2015-2020))
  • 13.1.5 Cepheid Recent Development
• 13.2 Koninklijke Philips N.V
  • 13.2.1 Koninklijke Philips N.V Company Details
  • 13.2.2 Koninklijke Philips N.V Business Overview
  • 13.2.3 Koninklijke Philips N.V Next Generation Cancer Diagnostics Introduction
  • 13.2.4 Koninklijke Philips N.V Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.2.5 Koninklijke Philips N.V Recent Development
• 13.3 F. Hoffmann-La Roche Ltd
  • 13.3.1 F. Hoffmann-La Roche Ltd Company Details
  • 13.3.2 F. Hoffmann-La Roche Ltd Business Overview
  • 13.3.3 F. Hoffmann-La Roche Ltd Next Generation Cancer Diagnostics Introduction
  • 13.3.4 F. Hoffmann-La Roche Ltd Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.3.5 F. Hoffmann-La Roche Ltd Recent Development
• 13.4 Qiagen
  • 13.4.1 Qiagen Company Details
  • 13.4.2 Qiagen Business Overview
  • 13.4.3 Qiagen Next Generation Cancer Diagnostics Introduction
  • 13.4.4 Qiagen Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.4.5 Qiagen Recent Development
• 13.5 Novartis AG
  • 13.5.1 Novartis AG Company Details
  • 13.5.2 Novartis AG Business Overview
  • 13.5.3 Novartis AG Next Generation Cancer Diagnostics Introduction
  • 13.5.4 Novartis AG Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.5.5 Novartis AG Recent Development
• 13.6 Abbott
  • 13.6.1 Abbott Company Details
  • 13.6.2 Abbott Business Overview
  • 13.6.3 Abbott Next Generation Cancer Diagnostics Introduction
  • 13.6.4 Abbott Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.6.5 Abbott Recent Development
• 13.7 Thermo Fisher Scientific
  • 13.7.1 Thermo Fisher Scientific Company Details
  • 13.7.2 Thermo Fisher Scientific Business Overview
  • 13.7.3 Thermo Fisher Scientific Next Generation Cancer Diagnostics Introduction
  • 13.7.4 Thermo Fisher Scientific Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.7.5 Thermo Fisher Scientific Recent Development
• 13.8 Opko Health
  • 13.8.1 Opko Health Company Details
  • 13.8.2 Opko Health Business Overview
  • 13.8.3 Opko Health Next Generation Cancer Diagnostics Introduction
  • 13.8.4 Opko Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.8.5 Opko Health Recent Development
• 13.9 Myriad Genetics
  • 13.9.1 Myriad Genetics Company Details
  • 13.9.2 Myriad Genetics Business Overview
  • 13.9.3 Myriad Genetics Next Generation Cancer Diagnostics Introduction
  • 13.9.4 Myriad Genetics Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.9.5 Myriad Genetics Recent Development
• 13.10 Agilent Technologies
  • 13.10.1 Agilent Technologies Company Details
  • 13.10.2 Agilent Technologies Business Overview
  • 13.10.3 Agilent Technologies Next Generation Cancer Diagnostics Introduction
  • 13.10.4 Agilent Technologies Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 13.10.5 Agilent Technologies Recent Development
• 13.11 GE Healthcare
  • 10.11.1 GE Healthcare Company Details
  • 10.11.2 GE Healthcare Business Overview
  • 10.11.3 GE Healthcare Next Generation Cancer Diagnostics Introduction
  • 10.11.4 GE Healthcare Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.11.5 GE Healthcare Recent Development
• 13.12 PerkinElmer
  • 10.12.1 PerkinElmer Company Details
  • 10.12.2 PerkinElmer Business Overview
  • 10.12.3 PerkinElmer Next Generation Cancer Diagnostics Introduction
  • 10.12.4 PerkinElmer Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.12.5 PerkinElmer Recent Development
• 13.13 Genomic Health
  • 10.13.1 Genomic Health Company Details
  • 10.13.2 Genomic Health Business Overview
  • 10.13.3 Genomic Health Next Generation Cancer Diagnostics Introduction
  • 10.13.4 Genomic Health Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.13.5 Genomic Health Recent Development
• 13.14 Illumina
  • 10.14.1 Illumina Company Details
  • 10.14.2 Illumina Business Overview
  • 10.14.3 Illumina Next Generation Cancer Diagnostics Introduction
  • 10.14.4 Illumina Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.14.5 Illumina Recent Development
• 13.15 Hologic
  • 10.15.1 Hologic Company Details
  • 10.15.2 Hologic Business Overview
  • 10.15.3 Hologic Next Generation Cancer Diagnostics Introduction
  • 10.15.4 Hologic Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.15.5 Hologic Recent Development
• 13.16 Almac Group
  • 10.16.1 Almac Group Company Details
  • 10.16.2 Almac Group Business Overview
  • 10.16.3 Almac Group Next Generation Cancer Diagnostics Introduction
  • 10.16.4 Almac Group Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.16.5 Almac Group Recent Development
• 13.17 Janssen Global Services
  • 10.17.1 Janssen Global Services Company Details
  • 10.17.2 Janssen Global Services Business Overview
  • 10.17.3 Janssen Global Services Next Generation Cancer Diagnostics Introduction
  • 10.17.4 Janssen Global Services Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.17.5 Janssen Global Services Recent Development
• 13.18 Sysmex Corporation
  • 10.18.1 Sysmex Corporation Company Details
  • 10.18.2 Sysmex Corporation Business Overview
  • 10.18.3 Sysmex Corporation Next Generation Cancer Diagnostics Introduction
  • 10.18.4 Sysmex Corporation Revenue in Next Generation Cancer Diagnostics Business (2015-2020)
  • 10.18.5 Sysmex Corporation Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer